Pragma Bio, a South San Francisco-based tech platform for drug discovery, revealed it secured $10M in equity funding.
The company plans to use the funds to develop proprietary methods in genomic sequencing and synthetic biology to develop therapies for immune system disorders.
The company developed Lattice, which archives interactions and correlations between natural products and human cells.
- The new funds add to a round total of $15M with participation from the Merck Global Health Innovation Fund, Viking Global Investors, and CJ Investments.
- The company’s previous round was a $4.5M Seed with participation from Timewise Investment, in addition to Merck and Viking Global.
- Pragma received a $15,000 grant from Texas A&M’s new venture competition.
